• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Technology Bio Tech

Reality Bites for Cochlear, as Share Price is Buoyed by Hopeful Outlook

Like 0

By Ryan Clarkson-Ledward, Tuesday, 18 August 2020

Despite this historic loss, the market managed to see the brighter side of things, with shareholders overlooking the recent downturn to see a far more optimistic future. That has helped the COH share price climbed by 9.89% at time of writing — the highest levels it has seen since February....

Earnings season has delivered yet another surprise.

Cochlear Ltd [ASX:COH] was the big standout today, reporting its first net loss since listing on the ASX back in December 1995.

Suffice to say, that is not the kind of news that shareholders like to hear (no pun intended).

Despite this historic loss, the market managed to see the brighter side of things, with shareholders overlooking the recent downturn to see a far more optimistic future.

That has helped the COH share price climbed by 9.89% at time of writing — the highest levels it has seen since February.

Two starkly different halves of the year

For Cochlear, it was the very definition of an up and down year, with the first half delivering decent growth, and the second half seeing a massive shortfall.

Revenue was up 9% to 31 December before cratering by 22% in the half of 2020 (to 30 June) thanks to the pandemic.

April in particular was a terrible month for the company, seeing an 80% fall in revenues from implant surgery.

All of these factors combined led to an underlying net profit of $153.8 million — 42% shy of last year’s tally.

But that wasn’t all.

The real kicker for Cochlear, and the thing that has driven its bottom line into the red, was a $416.3 million legal bill. The company was forced to pay this sum after a bitter patent dispute didn’t end in its favour.

Because of that, Cochlear has reported its first ever net loss as a public company, reporting a $238.3 million hit to its bottom line.

It is a painful result, but at least it is over.

And despite the loss, the company is already looking ahead, with plenty of opportunities in the mix. Namely, the rapid change that this pandemic is bringing to healthcare as a whole:

‘The pandemic has also driven the rapid adoption of telehealth and telemedicine which may lead to faster than expected structural changes in healthcare delivery. We experienced this first hand with the FDA fast-tracking the approval of our Remote Check solution in the US.

‘Our professional partners too have shown greater interest and demand for our connected care solutions over the last few months which also include Cochlear Link and Remote Programming in many markets.

‘We have been investing in connected care solutions for many years and believe they provide the opportunity to open up access to our products and optimise outcomes for recipients by transforming the care model while delivering efficiencies to clinics.’

So, all in all, Cochlear could move on to bigger and better things pretty quickly.

Indeed, revenues are already starting to bounce back, which is no doubt a big reason for the share price rising today, even with the underlying net loss.

This begs the question: Is now a good time to invest in this healthcare juggernaut?

Plenty of potential

There is no doubt that this could be a turning point for Cochlear. A moment that sees the company move to even higher highs.

Whether or not it can make it happen, though, is impossible to say.

There are no guarantees when it comes to investing, after all. No matter how big or cashed up the company may be.

Cochlear is certainly a company worth keeping an eye on though. Especially if you’re looking for a less risky exposure to the healthcare sector. After all, I’d be surprised if Cochlear reported another net loss by the end of our current financial year.

Having said that, there are potentially better stocks to keep an eye on too.

It is hard to ignore the incredible performance at the smaller end of the market, with many stocks outpacing and outperforming the large-caps significantly.

That’s why we suggest looking out for high-value small-cap plays. That is, stocks that have the potential to deliver exponential returns.

To learn more, check out our full report right here.

Regards,

Ryan Clarkson-Ledward,
For Money Morning

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Ryan Clarkson-Ledward

Ryan’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • OpenAI and Microsoft Divorce?: Why this could be good for you
    By Charlie Ormond

    While breakups are rarely pretty, this one might actually benefit investors willing to look beyond the drama.

  • Three Lithium Stocks in the Buy Zone
    By Murray Dawes

    Lithium stocks jumped this week, so Murray and Callum discuss whether this could be the beginning of the second boom in lithium stocks. They also discuss a fund manager that is recovering and looking cheap

  • Every Australian Investor Has a Stake in Mining
    By James Cooper

    With its deep pool of retirement capital, Australia is on track to become the world’s primary destination for resource markets.

Primary Sidebar

Latest Articles

  • OpenAI and Microsoft Divorce?: Why this could be good for you
  • Three Lithium Stocks in the Buy Zone
  • Every Australian Investor Has a Stake in Mining
  • The next wave of AI winners
  • Could the US People Repudiate the National Debt?

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988